Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering aims to fund Phase 2 clinical trials for EYP-1901, targeting wet AMD, diabetic retinopathy, and retinal vein occlusion. The proceeds will also support earlier stage pipeline initiatives and general corporate purposes. The securities are offered under a previously filed registration statement, and the offering's completion is subject to market conditions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced promising six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an investigational treatment for wet age-related macular degeneration (wet AMD). The trial demonstrated a favorable safety profile with no ocular serious adverse events and a 79% reduction in treatment burden. Notably, 76% and 53% of patients did not require rescue treatments up to four and six months, respectively. EyePoint plans to initiate a Phase 2 trial in 2022 and has a Type C meeting with the FDA scheduled for December 1, 2021, to discuss registration trials.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced encouraging six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an anti-VEGF treatment for wet age-related macular degeneration (AMD). Presented at the AAO 2021 Meeting, the trial involved 17 patients, showcasing a 79% reduction in treatment burden and no serious adverse events reported. Patients experienced sustained visual acuity with 76% and 53% not needing rescue therapy after four and six months, respectively. EyePoint plans to advance EYP-1901 into Phase 2 trials in 2022 and engage with the FDA regarding registration trials.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will have CEO Nancy Lurker present at two virtual conferences: the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET and the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The company focuses on developing therapeutics for serious eye disorders, including its Durasert® technology. Webcasts of the presentations will be available on their website, with replays accessible for 30 and 90 days, respectively.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on November 13 at 12:00 P.M. ET to discuss interim data from its Phase 1 DAVIO trial of EYP-1901, aimed at treating wet AMD. The interim results will be presented by Dr. David Boyer during the AAO Retina Subspecialty Day. EYP-1901 is designed for sustained drug delivery through the company's proprietary Durasert technology, which may provide a twice-yearly treatment option for patients. The event will be accessible via phone and webcast on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported its Q3 2021 financial results, highlighting a 49% increase in net product revenue, totaling $8.6 million compared to $5.8 million in the same quarter last year. The Company presented positive safety data from the Phase 1 DAVIO trial for EYP-1901 targeting wet AMD at the ASRS 2021 Annual Meeting. Operating expenses rose to $24.4 million, leading to a net loss of $16.7 million or ($0.58) per share. However, cash reserves improved to $119.7 million, supporting operations through 2022.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Dr. Jay S. Duker as Chief Operating Officer, expanding his role from Chief Strategic Scientific Officer. Dr. Duker, who has been part of the EyePoint team since 2020, has extensive experience in retinal disease and entrepreneurship. His leadership aims to enhance EyePoint's development of next-generation ophthalmic therapeutics, including the promising EYP-1901 for wet AMD. The company is excited about his ability to lead clinical and product development as it strives to address significant eye disorders.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will host a conference call on November 3, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and recent business developments. This call is part of the company's commitment to improving therapeutics for serious eye disorders, utilizing its proprietary Durasert® technology. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, alongside its commercial products, YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive interim safety data from its Phase 1 DAVIO clinical trial of EYP-1901 for wet age-related macular degeneration. The trial shows no serious ocular or systemic adverse events after 3 months, indicating a robust safety profile. Additionally, the ongoing YUTIQ® CALM registry study continues to gather real-world data on patients treated with fluocinolone acetonide intravitreal implant. EYP-1901 aims to offer a twice-yearly treatment solution for patients suffering from this retinal disease.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the selection of a late-breaking abstract for the Phase 1 DAVIO trial of EYP-1901 in wet age-related macular degeneration (AMD) for presentation at the American Academy of Ophthalmology 2021 Annual Meeting, scheduled for November 12-15, 2021.
The presentation will feature topline data and is set for November 13, 2021, at 9:07 AM CST, presented by David S. Boyer MD. EYP-1901 aims to provide sustained delivery treatment via a single injection, with key endpoints including safety and visual acuity.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
